Illumina Q3 revenue rises but misses estimates; lifts outlook
Illumina Q3 revenue rises but misses estimates; lifts outlook
Overview
DNA sequencing tech firm's fiscal Q3 revenue rose 4% yr/yr but missed analyst expectations
Adjusted EPS for fiscal Q3 beat analyst expectations
Company raised full-year revenue and earnings guidance, citing clinical demand and NovaSeq X placements
Outlook
Illumina raises 2026 revenue guidance to $4.64-$4.66 bln, up from $4.60-$4.64 bln
Company now sees 2026 non-GAAP diluted EPS at $5.40-$5.45, up from $5.30-$5.40
Illumina maintains 2026 organic revenue growth outlook above 4% and ROW organic growth above 5%
Result Drivers
CLINICAL DEMAND - Co said healthy clinical demand contributed to Q3 results
NOVASEQ X PLACEMENTS - Robust NovaSeq X placements supported Q3 performance, per CEO Jacob Thaysen
Company press release: ID:nPn3V59cxa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $1.13 bln | $1.15 bln (18 Analysts) |
Q3 Adjusted EPS | Beat | $1.62 | $1.36 (18 Analysts) |
Q3 EPS |
| $1.43 |
|
Q3 Gross Margin |
| 73.50% |
|
Q3 Adjusted Gross Margin |
| 75.30% |
|
Q3 EBIT Margin |
| 27.00% |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 10 "strong buy" or "buy", 9 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Illumina Inc is $272.50, about 5.6% below its October 28 closing price of $288.79
The stock recently traded at 48 times the next 12-month earnings vs. a P/E of 32 three months ago
Reuters Recommended Reads
Oct 27 - Seagate Technology Q1 revenue and adjusted EPS beat estimates
Oct 28 - Avantor raises FY revenue growth, profit guidance after Q3 beat
Oct 28 - Biogen Q3 revenue beats on Apellis acquisition, product demand
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Illumina
See all newsBrief: Illumina Advances MRD Research Portfolio With Ultrasensitive Duplex Sequencing Technology
US STOCKS ON THE MOVE-Global Payments, Aspen Neuroscience, Illumina
U.S. STOCKS ON THE MOVE-FedEx Freight, AbbVie, Intel
Illumina falls on Q3 revenue miss
Illumina Inc reports results for the quarter ended September 30 - Earnings Summary